GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anteris Technologies Global Corp (ASX:AVR) » Definitions » 12-1 Month Momentum %

Anteris Technologies Global (ASX:AVR) 12-1 Month Momentum % : -45.35% (As of Mar. 03, 2025)


View and export this data going back to 2004. Start your Free Trial

What is Anteris Technologies Global 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2025-03-03), Anteris Technologies Global's 12-1 Month Momentum % is -45.35%.

The industry rank for Anteris Technologies Global's 12-1 Month Momentum % or its related term are showing as below:

ASX:AVR's 12-1 Month Momentum % is ranked worse than
83.91% of 845 companies
in the Medical Devices & Instruments industry
Industry Median: -9.55 vs ASX:AVR: -45.35

Competitive Comparison of Anteris Technologies Global's 12-1 Month Momentum %

For the Medical Devices subindustry, Anteris Technologies Global's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anteris Technologies Global's 12-1 Month Momentum % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies Global's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Anteris Technologies Global's 12-1 Month Momentum % falls into.


Anteris Technologies Global  (ASX:AVR) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anteris Technologies Global  (ASX:AVR) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Anteris Technologies Global 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Anteris Technologies Global's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Anteris Technologies Global Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anteris Technologies Global Corp (ASX:AVR) » Definitions » 12-1 Month Momentum %
Comparable Companies
ASX:IMR ASX:ARX ASX:4DX ASX:EMV ASX:SOM ASX:IPD ASX:RSH ASX:COV ASX:CMP ASX:CVB ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA STE
Traded in Other Exchanges
N/A
Address
9 Sherwood Road, Level 3, Suite 302, Toowong Tower, Toowong, QLD, AUS, 4066
Website
https://www.anteristech.com
Anteris Technologies Global Corp is a structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Its product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with the world's interventional cardiologists and cardiac surgeons to treat aortic stenosis - a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow.